Physician profile
Laura Behm
NPI 1275903916
$772.48
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $388 · 2022: $353 · 2024: $31.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $31.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $31.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $90.45 | 2021-2022 | |
| Ucb, INC. | $90.01 | 2021-2022 | |
| Lundbeck LLC | $69.07 | 2021-2022 | |
| Biogen, INC. | $49.55 | 2022 | |
| Alexion Pharmaceuticals, INC. | $47.23 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $41.59 | 2022 | |
| Amneal Pharmaceuticals LLC | $39.48 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $36.80 | 2021-2022 | |
| Genzyme Corporation | $34.42 | 2021-2022 | |
| Corium, LLC | $31.90 | 2024 | Azstarys |
| Biohaven Pharmaceutical Holding Company Ltd. | $28.42 | 2022 | |
| Arbor Pharmaceuticals, INC. | $27.97 | 2021 | |
| Lilly USA, LLC | $25.70 | 2021 | |
| Amgen INC. | $25.37 | 2022 | |
| Neurelis, INC. | $24.79 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cognoa, INC. | $24.63 | 2021 | |
| Upsher-Smith Laboratories LLC | $23.19 | 2021 | |
| Celgene Corporation | $23.18 | 2021 | |
| Allergan, INC. | $22.35 | 2021 | |
| Abbvie INC. | $16.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Behm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.